Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
ACS Omega|July 31, 2023
Synthesis of Structurally Related Coumarin Derivatives as Antiproliferative AgentsEzequiel F Bruna-Haupt, Marcelle D Perretti, Hugo A Garro, et al.
Physics in Medicine and Biology|January 18, 2024
Material decomposition maps based calibration of dual energy CT scanners for proton therapy planning: a phantom studyDavid Viar-Hernández, Juan Antonio Vera-Sánchez, Lucia Schmidt-Santiago, et al.
Chemotherapy Research and Practice|April 7, 2012
Clear-cell adenocarcinoma of vesical origin: a case study of metastatic disease treated with chemotherapyCarolina Pena Álvarez, Isabel Lorenzo Lorenzo, Silvia Varela Ferreiro, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|March 15, 2024
Generation of a humanized mAce2 and a conditional hACE2 mouse models permissive to SARS-COV-2 infectionI-Wen Song, Megan Washington, Carolina Leynes, et al.
Disease Models & Mechanisms|July 24, 2023
Delayed skeletal development and IGF-1 deficiency in a mouse model of lysinuric protein intoleranceBridget M Stroup, Xiaohui Li, Sara Ho, et al.
Human Molecular Genetics|May 12, 2011
Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3Xiaoming Wang, Portia A McCoy, Ramona M Rodriguiz, et al.
Diabetologia|January 28, 2016
PAX4 preserves endoplasmic reticulum integrity preventing beta cell degeneration in a mouse model of type 1 diabetes mellitusJosé Manuel Mellado-Gil, Carmen María Jiménez-Moreno, Alejandro Martin-Montalvo, et al.
Aging|September 14, 2019
Inadequate control of thyroid hormones sensitizes to hepatocarcinogenesis and unhealthy agingLivia López-Noriega, Vivian Capilla-González, Nadia Cobo-Vuilleumier, et al.
Ecancermedicalscience|March 4, 2026
Oncology with common sense: beyond biologistic and pharmacological modelsRodrigo Lastra, Patricia Iranzo, Javier-David Benítez-Fuentes, et al.
Nature Communications|April 4, 2026
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trialJaume Capdevila, Jorge Hernando, Javier Molina-Cerillo, et al.
Pageof 6